finance.yahoo.com
Cure8 news brief
Why This Matters
This press release announces upcoming presentations of early clinical and biomarker data for PALI-2108, a gut‑targeted oral PDE4 prodrug being developed for UC and Crohn’s disease. Patients and clinicians may see new Phase 1b data and a biomarker aimed at predicting treatment response at UEG Week 2026.
If PALI-2108 shows reproducible efficacy with favorable safety and a validated predictive biomarker, it could become an additional oral treatment option for IBD in the future.
Who Should Pay Attention
Patients with ulcerative colitis or Crohn’s disease interested in new oral treatments; clinicians who treat IBD; researchers focused on IBD drug development, PDE4 mechanisms, or biomarkers.
Study Snapshot
Story typeCompany update
Evidence typePhase 1 clinical trial
Source depthFull source text
What To Know
Palisade Bio announced that its oral PDE4 prodrug PALI-2108 will be presented at UEG Week 2026 with Phase 1b data in fibrostenotic Crohn’s disease and additional posters reporting early clinical activity in ulcerative colitis, gut-targeted exposure, safety/tolerability, and a transcriptomic biomarker to predict response.
The release describes PALI-2108 as a gut-activated, once-daily PDE4 inhibitor being advanced into Phase 2. The article is a company press release summarizing planned conference presentations rather than a peer-reviewed paper; it highlights early Phase 1b findings and translational biomarker work but does not provide detailed results in this text.
The biomarker development and Phase 1b oral presentation are the central items reported. If you follow advances in IBD treatments, this signals an emerging oral PDE4 prodrug entering Phase 2 and that data will be presented at UEG Week; watch for the conference abstracts or full posters for detailed efficacy and safety data.
Keep In Mind
This is a company press release describing planned conference presentations and early Phase 1b data; the text does not include full trial results or independent peer review. Wait for the conference abstracts, posters, or peer-reviewed publications for detailed methods and outcomes before drawing conclusions about effectiveness or safety.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationfinance.yahoo.com
PublisherYahoo! Finance
AuthorsPalisade Bio, Inc.
Indexed viaBing News
Source typeWeb article
PublishedSep 28, 2026, 5:50 AM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Wolfe Highlights Differentiation Potential in Palisade Bio, Inc. (PALI) Clinical Profile
Early clinical data suggest PALI-2108 may affect both inflammation and fibrosis in Crohn’s disease and shows biomarker changes (like fecal calprotectin) that could matter to people monitoring disease activity.
Palisade Bio, Inc. (PALI) Presents at Morgan Stanley 24th Annual Global Healthcare ...
An orally dosed, gut-targeted PDE4 prodrug entering Phase 2 could offer a new locally acting anti-inflammatory option for people with UC or Crohn’s, potentially with fewer systemic side effects than older PDE4 drugs.
PALISADE BIO, INC. Q2 2026: Revenue $0.5M, EPS $(0.05) — 10-Q Summary
If you or a loved one follow emerging IBD treatments, this update signals a new PALI-2108 program moving into Phase 2 for ulcerative colitis and planned Phase 2 testing in Crohn’s disease, plus a company focus on...